Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ASCO data bring new markets within reach for two AstraZeneca therapies

The challenge for AZ’s Tagrisso, Enhertu will be persuading doctors to adopt genetic testing

AstraZeneca stole the show at ASCO on Friday with data that should help propel its top-grossing cancer drug and one of its newest market entrants into broadly expanded patient populations, as long as physicians adopt genetic testing in the new indications.

AstraZeneca plc (LSE:AZN; NYSE:AZN) reported at the American Society of Clinical Oncology meeting that Tagrisso osimertinib increased disease-free survival in an adjuvant setting for early-stage, EGFR-mutant non-small cell lung

Read the full 699 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers